- Home
- JHI vs IVVD Comparison
JHI vs IVVD Comparison
Compare JHI & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHI
- IVVD
- Stock Information
- Founded
- JHI 1971
- IVVD 2020
- Country
- JHI United States
- IVVD United States
- Employees
- JHI N/A
- IVVD N/A
- Industry
- JHI Trusts Except Educational Religious and Charitable
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- JHI Finance
- IVVD Health Care
- Exchange
- JHI Nasdaq
- IVVD Nasdaq
- Market Cap
- JHI 124.0M
- IVVD 116.8M
- IPO Year
- JHI N/A
- IVVD 2021
- Fundamental
- Price
- JHI $14.07
- IVVD $0.70
- Analyst Decision
- JHI
- IVVD Strong Buy
- Analyst Count
- JHI 0
- IVVD 5
- Target Price
- JHI N/A
- IVVD $7.11
- AVG Volume (30 Days)
- JHI 29.5K
- IVVD 581.2K
- Earning Date
- JHI 01-01-0001
- IVVD 11-14-2024
- Dividend Yield
- JHI 6.80%
- IVVD N/A
- EPS Growth
- JHI N/A
- IVVD N/A
- EPS
- JHI 1.05
- IVVD N/A
- Revenue
- JHI N/A
- IVVD $11,564,000.00
- Revenue This Year
- JHI N/A
- IVVD N/A
- Revenue Next Year
- JHI N/A
- IVVD $72.22
- P/E Ratio
- JHI $12.47
- IVVD N/A
- Revenue Growth
- JHI N/A
- IVVD N/A
- 52 Week Low
- JHI $11.63
- IVVD $0.71
- 52 Week High
- JHI $13.40
- IVVD $5.20
- Technical
- Relative Strength Index (RSI)
- JHI 46.43
- IVVD 33.40
- Support Level
- JHI $14.05
- IVVD $0.72
- Resistance Level
- JHI $14.13
- IVVD $0.81
- Average True Range (ATR)
- JHI 0.12
- IVVD 0.07
- MACD
- JHI -0.02
- IVVD -0.02
- Stochastic Oscillator
- JHI 21.87
- IVVD 1.12
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.